Inhibitory effect of 131I-CD133mAb combined with cisplatin on liver cancer cells in vitro and in a tumor-bearing mouse model
10.3969/j.issn.1673-4254.2014.07.04
- VernacularTitle:131I-CD133mAb联合顺铂在体内外有效抑制人肝癌细胞的生长
- Author:
Xingyue CHEN
1
;
Yanli HOU
;
Liqun DUAN
;
Min TANG
;
Qiangqiang KANG
;
Jin SHU
;
Zhiping PENG
;
Shaolin LI
Author Information
1. 重庆医科大学基础医学院放射医学教研室
- Keywords:
liver cancer;
CD133;
cisplatin;
radioimmunotherapy;
131I
- From:
Journal of Southern Medical University
2014;(7):934-938
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the inhibitory effect of CD133 monoclonal antibody labeled with 131I (131I-CD133mAb) on Huh-7 human liver cancer cell line overexpressing CD133 antigen in vitro and in mouse models bearing the tumor cell xenograft. Methods 131I-CD133mAb was prepared by chloramines-T method and evaluated for its stability. Flow cytometry and immunohistochemistry were used to detect the expression of CD133 in Huh-7 cells and in Huh-7 cell-derived tumors, respectively. Huh-7 cells treated with 131I-CD133mAb plus cisplatin (DDP), 131I-CD133mAb, DDP, or no treatment (blank control) were examined for cell proliferation suppression by MTT assay with the IC50 calculated. BALB/c mice bearing subcutaneous Huh-7 cell xenograft in the right forelegs were treated with 131I-CD133mAb, DDP, or both every two days for two weeks. The tumor size and volume were measured twice a week, and pathological examination of the tumor was carried out after the treatments. The tumor inhibition rate was calculated and tumor cell apoptosis observed with HE staining. Results The labeling ratio of 131I-CD133mAb was 90.25% and the radiochemical purity was 97.78%. Huh-7 cells showed obviously higher CD133 expression than HepG2 cells. 131I-CD133mAb combined with DDP group resulted in a significantly higher tumor inhibition rate than other treatments in the tumor-bearing mice. Conclusion 131I-CD133mAb can inhibit the growth of liver cancer cells with a high CD133 expression both in vivo and in vitro.
